Hy2Care raises € 3.7 million in funding

30 / 04 / 2019 | Redactie

Hy2Care BV, a spin-off of the University of Twente founded by professor Marcel Karperien, has managed to raise € 3.7 million in funding. The startup, which has developed injectable hydrogels for the treatment of cartilage defects, will now be able to commercialize its technology for veterinary use as well as initiate human trials.

Photo by: Emiel Muijderman

Hy2Care was founded in 2014 by a UT professor Marcel Karperien. Together with his team of the Developmental BioEngineering group, Karperien has invented a new hydrogel device for repairing cartilage defects. The hydrogel technology enables a fast repair of acute cartilage defects that often occur as a result of falls, accidents and sports injuries.

The startup is located on campus of the University of Twente and will also set up new offices and laboratory facilities in the South of Limburg. Upon closing of the investment, the company will be joined by Leo Smit is its new CEO, while Professor Karperien will continue fulfilling the role of Chief Scientific Officer.

Veel lamabloed bevat antilichamen die de pijn van artrosepatiënten misschien kunnen verlichten. UT-hoogleraar Marcel Karperien werkt aan een technologie om deze antilichamen toe te dienen. Hoewel de combinatie van wetenschap en ondernemen soms leidt tot botsende belangen, hebben universiteit en bedrijfsleven elkaar volgens Karperien hard nodig.

06 / 10 / 2023

Using llama blood to relieve osteoarthritis pain

Llama blood contains antibodies that may potentially relieve the pain of osteoarthritis patients. UT professor Marcel Karperien is working on a technology to administer these antibodies. Although the combination of science and entrepreneurship sometimes leads to clashing interests, Karperien says that the university and business community sorely need each other.